

KEDIA ADVISORY

Researching Wealth

Stock basket performance snapshot as on 02nd November 2023

KEDIA ADVISORY

STOCK — BASKETS

Research Advisory | White Labelling | Digital Marketing
www.kediaadvisory.com

About Us

Incorporated in 2004 as Kedia Commodities by Mr. Vijay Kedia. Later on, diversified business into other segments of Financial Markets i.e. Equities, Currencies & Mutual Funds becoming India's 1st Unified Licensed Stock Broker approved by SEBI - 2017.

Today, we offer a wide range of Financial Product & Services from Equities to AIF under one account. A User-Friendly Multi-Asset Trading Platform encompasses Robust Back Office Support. We are Members of NSE, BSE, MCX, NCDEX, ICEX, and CDSL and are regulated by SEBI.

Mission & Vision

- To emerge as the one-stop resource and comprehensive solution provider that every investor can contact for all investment needs, support, and advice.
- To reach out to all those investors (retail and corporate), who wish To maximize their returns and be able To easily diversify their portfolios.
- To offer research and personalized services that empower investment with timely updates about the Financial Markets
- To help individuals in creating, managing & preserving Wealth over the long-term horizon.

Awards, Achievement & Recognitions

- Business Excellence Award by Zee Business, 2016
- 1st Company in the Country with Unified Stock Broking License Approved by SEBI, 2017
- Best Commodity Advisory Company Awarded by MCX, 2018
- Best Commodity Advisory by NCDEX, 2021
- Presence as Opinion Board of Zee Business, CNBC, ET Now & other prominent Business Channels

Management

Mr. Vijay Kedia Founder & Managing Director

Mr. Ajay Kedia Director & Head of Research

Mr. Aakash Bansal Director & Business Head

Mr. Sanchit Taksali, CFP[®]CM Independent Director

Introduction

"Wealth can only be created, if it is Managed wisely while Preserving its Legacy."

In the last 40 years, the Indian Stock Market has given an annualized return of 15% i.e. bringing the compounding effect of money doubling in every 5 Years. Thus, any investor who stays invested in the Indian Stock Market with a corpus of just Rs. 100 in the 1980s has created a wealth of Rs. 26,786.35/- (the Year 2021) which is a whopping 267x multiple of return over the period.

Wealth comes with an option of Time. It has been proven, that investors who follow the Strategy of Asset Allocation created wealth for themselves as well as for their Future Generations.

Creating Wealth is not just about Equity Investments - It is more of an Asset Allocation into the Right Asset Classes with Proper Diversification. In India, before 1992, the Asset Classes has been limited to Real Estate, Stocks, Mutual Funds, Gold, Silver & Other Precious metals. With Globalization & Liberalization comes into the effect, the traditional Asset Classes have been transformed into Alternative Investments. Offering Investors, the option to choose varieties of products/services for their Portfolio.

As a great saying,

"With more Power comes, Greater Responsibilities."

Similarly,

"With more Investment Options, the greater are the chances to hedge against the unknown Risk."

"At Kedia Capital Services, we always believe in providing Quality Services to both our team as well as to our customers.

Thus, in the year 2020, after the approval of the SEBI Registered Investment Advisory License - We started diversifying our Product/Service Basket to provide our prestigious clients with Right Investment Avenues under an umbrella.

Resulting in, Save Time, Effort & Cost in our customer's pockets.

Investing Money is Simple, but Managing these investments requires expertise & experience which, at Kedia Capital Services incorporated at its root since 2004.

And will continue to do so..."

"This is our Monthly Recommended Portfolio Performance Report for our esteemed Clients & our Internal Team members for reference purposes. Thus, benefiting both on an individual basis as well as on a societal basis.

Along with this, it will also, acknowledge our customers in enriching their Knowledge about the available Investment Avenues & the Risk-Reward payoff offered by such avenues.

Investments in any Financial Instruments are Subject to Market Risk. Please Always Consult with SEBI's Registered Investment Advisor or Kedia's Wealth Advisor, before taking any investment Decision.

At Kedia Capital Services, we continuously try to aware as many individuals as possible of Financial Literacy & Inclusion through Investor Awareness Program, Online Webinars, Weekend's #KediaTalks, and much more.

**Mr. Ajay Kedia,
(Director)**

**Mr. Sanchit Taksali, CFP
(Independent Director)**

For participation, please get in touch with your RM.


Inception Date

August 23, 2021

No. of Stocks: 10

Benchmark: NIFTY DIVIDEND OPPORTUNITY 50

PERFORMANCE OF BASKET (1 Yr)




Strategy Snapshot

- Investors can invest in companies with high and sustainable dividend yields comparable to or higher than fixed income returns
- Investors should focus on companies with strong balance sheets, persistent competitive advantages, and are available at a discount to intrinsic values.
- The Super Normal portfolio currently with a high dividend yield.
- Further, the companies could grow and their dividends would increase as well.
- A portfolio can have significantly lower volatility as it is diversified into various sectors and industries


PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	57.61%	28.47%	31.78%	17.35%
BENCHMARK	20.08%	11.40%	23.22%	12.29%
ALPHA GENERATED	37.53%	17.07%	8.56%	5.06%

Minimum Investment Required: Rs. 50,000/- . SIP & Lumpsum Option Available




Equity Return Calculator

If you had made a LUMPSUM investment of **Rs 5,00,000** in a **Dividend Basket** 3 Years Ago, your Investment would be worth **Rs 10,92,932.43** with a profit of **+29.78%** (3-year CAGR)



PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	34.63%	18.74%	51.31%	34.20%
BENCHMARK	27.41%	14.60%	33.04%	18.59%
ALPHA GENERATED	7.22%	4.14%	18.27%	15.61%

Minimum Investment Required: Rs. 50,000/- . SIP & Lumpsum Option Available



Equity Return Calculator


If you had made a LUMP SUM investment of Rs 5,00,000 in a **Monopoly Basket** 3 Years Ago, your Investment would be worth **Rs 17,32,099.75** with a profit of **+51.31%** (3-year CAGR)

SNAPSHOT

No. of Stocks: 09

Benchmark: NIFTY CONSUMPTION

PERFORMANCE OF BASKET (1 Yr)






Strategy Snapshot

- More people in the middle class have more discretionary income, which is the amount of money they have left over after paying for things like food and housing.
- This revenue is used to purchase upscale goods like cosmetics, designer clothing, entertainment, etc.
- Transportation, food & beverage, education, entertainment & leisure facilities, and other areas will be directly impacted by the anticipated growth in discretionary expenditure during the coming ten years.
- Companies that are anticipated to gain from the expansion of the middle class in India are included in this stock basket.

PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	23.17%	13.96%	26.76%	19.32%
BENCHMARK	5.38%	8.85%	18.25%	12.23%
ALPHA GENERATED	17.79%	5.11%	8.51%	7.09%


Minimum Investment Required: Rs. 50,000/- . SIP & Lumpsum Option Available

BASKET PERFORMANCE



TOP CONSTITUENTS


SCRIPTS	ALLOCATION (%)	SECTOR
RELIANCE	11.40	ENERGY
ITC LTD	9.35	FMCG
TITAN	11.40	JEWELLERY



Equity Return Calculator


If you had made a LUMP SUM investment of Rs 5,00,000 in a Consumption Basket 3 Years Ago, your Investment would be worth Rs 10,18,396.03 with a profit of +26.76% (3-year CAGR)

SNAPSHOT



PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	39.27%	29.60%	51.16%	24.20%
BENCHMARK	27.64%	14.70%	33.12%	18.63%
ALPHA GENERATED	11.63%	14.90%	18.04%	5.57%

Minimum Investment Required: Rs. 55,000/- . SIP & Lumpsum Option Available



Equity Return Calculator


If you had made a LUMP SUM investment of Rs 5,00,000 in a Leader Next Basket 3 Years Ago, your Investment would be worth Rs 17,26,953.54 with a profit of +51.16% (3-year CAGR)

SNAPSHOT



PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	14.41%	9.74%	27.03%	17.01%
BENCHMARK	5.89%	4.01%	17.40%	12.68%
ALPHA GENERATED	8.52%	5.73%	9.63%	4.33%

Minimum Investment Required: Rs. 1,00,000/- . SIP & Lumpsum Option Available



Equity Return Calculator

If you had made a LUMPSSUM investment of **Rs 5,00,000** in an **NXT-25 PREMIUM Basket** 3 Years Ago, your Investment would be worth **Rs 9,61,387.23** with a profit of **+27.03%** (3-year CAGR)

No. of Stocks: 12	Benchmark: NIFTY PHARMA				
<h3 style="margin: 0;">PERFORMANCE OF BASKET (1 YEAR)</h3> <table border="1" style="margin-top: 10px; width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center;">PORTFOLIO</td> <td style="width: 50%; text-align: center;">BENCHMARK</td> </tr> <tr> <td style="text-align: center;">12.30%</td> <td style="text-align: center;">9.60%</td> </tr> </table>	PORTFOLIO	BENCHMARK	12.30%	9.60%	<h3 style="margin: 0;">Strategy Snapshot</h3> <ul style="list-style-type: none"> By 2025, the Indian pharmaceutical industry is anticipated to reach a value of \$100 billion. The pharmaceuticals market is dominated by branded generics, which account for around 80% of market revenues By 2025, the pharmaceutical industry is predicted to create 58,000 more job openings. The USFDA approved 336 Abbreviated New Drug Applications (ANDAs) from Indian businesses in 2019, accounting for 40% of all final ANDA approvals. Growth is anticipated to be fueled by a big pipeline of high-value pharmaceuticals and a drop in regulatory alerts for larger corporations.
PORTFOLIO	BENCHMARK				
12.30%	9.60%				


PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	12.30%	5.79%	25.57%	24.38%
BENCHMARK	9.60%	3.48%	9.37%	9.45%
ALPHA GENERATED	2.07%	2.31%	16.20%	14.93%

Minimum Investment Required: Rs. 55,000/- . SIP & Lumpsum Option Available

FUNDAMENTAL PARAMETERS	VALUATION PARAMETERS	BASKET PERFORMANCE																								
<h4 style="margin: 0;">Sector Allocation</h4> <p>BIO TECHNOLOGIES 8.3%</p> <p style="text-align: center;">PHARMACEUTICALS 83.3%</p>	<h4 style="margin: 0;">RISK PROFILE</h4> <p style="text-align: center;">Moderate Risk</p>	<h4 style="margin: 0;">BASKET PERFORMANCE</h4>																								
<h4 style="margin: 0;">TOP CONSTITUENTS</h4> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th>SCRIPTS</th> <th>SECTOR</th> <th>ALLOCATION (%)</th> </tr> </thead> <tbody> <tr> <td>TORRENT PHARMA</td> <td>PHARMA</td> <td>8.33</td> </tr> <tr> <td>LUPIN</td> <td>PHARMA</td> <td>8.33</td> </tr> <tr> <td>BIOCON</td> <td>BIOTECHNOLOGY</td> <td>8.33</td> </tr> </tbody> </table>	SCRIPTS	SECTOR	ALLOCATION (%)	TORRENT PHARMA	PHARMA	8.33	LUPIN	PHARMA	8.33	BIOCON	BIOTECHNOLOGY	8.33	<h4 style="margin: 0;">VALUATION PARAMETERS</h4> <table border="1" style="margin-top: 10px; width: 100%; border-collapse: collapse; text-align: center;"> <tr> <td>P/E VALUE</td> <td>Portfolio: 24.53</td> <td>Benchmark: 46.59</td> </tr> <tr> <td>PB RATIO</td> <td>Portfolio: 5.09</td> <td>Benchmark: 3.55</td> </tr> <tr> <td>SHARPE RATIO</td> <td>Portfolio: 1.11</td> <td>Benchmark: 0.92</td> </tr> <tr> <td>D/Y YIELD</td> <td>Portfolio: 0.92</td> <td>Benchmark: 1.39</td> </tr> </table>	P/E VALUE	Portfolio: 24.53	Benchmark: 46.59	PB RATIO	Portfolio: 5.09	Benchmark: 3.55	SHARPE RATIO	Portfolio: 1.11	Benchmark: 0.92	D/Y YIELD	Portfolio: 0.92	Benchmark: 1.39	<h4 style="margin: 0;">BASKET PERFORMANCE</h4>
SCRIPTS	SECTOR	ALLOCATION (%)																								
TORRENT PHARMA	PHARMA	8.33																								
LUPIN	PHARMA	8.33																								
BIOCON	BIOTECHNOLOGY	8.33																								
P/E VALUE	Portfolio: 24.53	Benchmark: 46.59																								
PB RATIO	Portfolio: 5.09	Benchmark: 3.55																								
SHARPE RATIO	Portfolio: 1.11	Benchmark: 0.92																								
D/Y YIELD	Portfolio: 0.92	Benchmark: 1.39																								


Equity Return Calculator

If you had made a LUMPSUM investment of Rs 5,00,000 in a Pharma Basket 3 Years Ago, your Investment would be worth Rs 10,38,043.78 with a profit of +25.57% (3-year CAGR)



PERFORMANCE (AS OF 02/11/23)	1 YEAR	2 YEAR (CAGR)	3 YEAR (CAGR)	5 YEAR (CAGR)
PORTFOLIO	43.90	19.73%	55.06%	17.98%
BENCHMARK	27.64	14.70%	33.12%	18.63%
ALPHA GENERATED	16.26	5.03%	21.94%	-0.65%

Minimum Investment Required: Rs. 50,000/- . SIP & Lumpsum Option Available



Equity Return Calculator


If you had made a LUMPSUM investment of Rs 5,00,000 in a Taksali MultiCap Basket 3 Years Ago, your Investment would be worth Rs 18,64,100.59 with a profit of +55.06% (3-year CAGR)

Date: 31st Oct. 2022

No. of ETFs: 6

Benchmark: NIFTY 50

PERFORMANCE OF BASKET (SINCE INCEPTION)



Strategy Snapshot

- **Strategy:** A Blend of MF & ETF to generate maximum return on investments for investors.
- A Blend of Investments into the International Markets with Bluechip Companies across the world.
- A Portfolio for investors who want to expose or Diversify their portfolio with respect to world markets.
- **Geographical Diversification**
- **Invest in Leaders & Innovators across the globe**
- **Potentially higher returns to INR Depreciation**
- **Possibilities for Growth**

PERFORMANCE (AS OF 02/11/23)	1 MONTH	3 MONTH	6 MONTHS	1 YEAR
PORTFOLIO	2.14	2.36%	7.15%	27.8%
BENCHMARK	-2.11%	-1.88%	5.42%	4.59%
ALPHA GENERATED	2.25%	4.24%	1.73%	23.21%

Minimum Investment Required: Rs. 50,000/- . SIP & Lumpsum Option Available

FUNDAMENTAL PARAMETERS

BASKET PERFORMANCE


TOP CONSTITUENTS

SCRIPTS	ALLOCATION (%)
MOST N100	18.57
HANGSENG BEES	16.66
NIFTY BEES	13.71

RISK PROFILE



GLOBAL BENCHMARK



COUNTRIES COVERED



USA



INDIA



HONG KONG

Equity Return Calculator

If you had made a LUMP SUM investment of Rs 5,00,000 in a **Global-Domestic Basket** Since the inspection, your Investment would be worth **Rs 6,39,000.00** with a profit of **+27.80%** since last 1 Year

OUR EXPERT ANALYSTS



MR. AJAY KEDIA

DIRECTOR
HEAD OF RESEARCH

Leading SEBI Registered Research House into the business since 2004.
With 18+ Years of Experience in Providing Technical & Fundamental Research
Services as Market Leader in Equities, Commodities & Currencies.



MR. SANCHIT TAKSALI, CFP

INDEPENDENT DIRECTOR,
HEAD OF INVESTMENTS

Independent Director
7+ years of Financial Industry Experience
Created awareness among 2000+ individuals and 30+ Corporates on Financial Literacy
Established a Club of 20k+ members on Clubhouse - The Indian Stock Market

DISCLAIMER

This Report is prepared and distributed by Kedia Stocks & Commodities Research Pvt Ltd. for information purposes only. The recommendations, if any, made herein are expressions of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale through KSCRPL nor any solicitation or offering of any investment /trading opportunity. These information/opinions/ views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by KSCRPL to be reliable. KSCRPL or its directors, employees, affiliates or representatives do not assume any responsibility for or warrant the accuracy, completeness, adequacy and reliability of such information/opinions/ views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of KSCRPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/opinions/views contained in this Report. The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by KSCRPL in any jurisdiction (other than India), where any action for such purpose (s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. KSCRPL requires such a recipient to inform himself about and to observe any restrictions at his own expense, without any liability to KSCRPL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

KEDIA STOCKS & COMMODITIES RESEARCH PVT. LTD.

SEBI REGISTRATION NUMBER. INH000006156

Email : info@kediaadvisory.com | URL : www.kediaadvisory.com | Contact : +91 8069159941

Regd.Off.: 1, 2, 3 & 4, 1st Floor, Tulip Bldg, Flower Valley Complex, Khadakpada Circle, Kalyan-(W), Mumbai-421301, Maharashtra

KEDIA ADVISORY

Researching Wealth



FOLLOW US



Regd.Off.: 1, 2, 3 & 4, 1st Floor, Tulip Bldg, Flower Valley Complex,
Khadakpada Circle,
Kalyan-(W), Mumbai-421301, Maharashtra

 /kediaadvisory

 @kediaadvisory

 @kediaadvisory

 /kediaadvisory